SEC Form 10-Q filed by Longboard Pharmaceuticals Inc.
$LBPH
Biotechnology: Pharmaceutical Preparations
Health Care
Unavailable
Unavailable
Save time and jump to the most important pieces.
| Date | Price Target | Rating | Analyst |
|---|---|---|---|
| 9/10/2024 | $60.00 | Buy | Truist |
| 7/1/2024 | $60.00 → $90.00 | Overweight | Cantor Fitzgerald |
| 5/1/2024 | $36.00 | Outperform | Robert W. Baird |
| 2/16/2024 | $40.00 | Buy | Citigroup |
| 10/24/2023 | $16.00 → $35.00 | Overweight | Cantor Fitzgerald |
| 4/27/2023 | $13.00 | Buy | B. Riley Securities |
| 2/14/2022 | $14.00 | Outperform | Wedbush |
The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini
Bexicaserin (LP352) received Breakthrough Therapy designation (BTD) for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) for patients two years of age or older Bexicaserin demonstrated a sustained, durable response in seizure reduction and a favorable safety and tolerability profile across a broad range of DEEs in an interim analysis of the Open-Label Extension (OLE) of the Phase 1b/2a PACIFIC Study Completed End of Phase 2 Meeting to discuss Longboard's global Phase 3 program for bexicaserin, which is on track to initiate in H2 2024 Longboard plans to host an Investor & Analyst Event on September 16 to highlight details of the global P
Conference call to discuss corporate updates, including Phase 1 single ascending dose (SAD) topline data for LP659 in healthy volunteers Conference call and webcast to be held August 1 at 4:30pm ET (1:30pm PT) Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it plans to release second quarter 2024 financial results and provide a corporate update, including topline Phase 1 SAD data for LP659, its centrally acting, highly selective sphingosine-1-phosphate (S1P) receptor modulator, on August 1, 2024. The Company will host a conference call and we
SC TO-T/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 14D9/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC TO-T/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)
Truist initiated coverage of Longboard Pharmaceuticals with a rating of Buy and set a new price target of $60.00
Cantor Fitzgerald reiterated coverage of Longboard Pharmaceuticals with a rating of Overweight and set a new price target of $90.00 from $60.00 previously
Robert W. Baird initiated coverage of Longboard Pharmaceuticals with a rating of Outperform and set a new price target of $36.00
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SC 13G/A - Longboard Pharmaceuticals, Inc. (0001832168) (Subject)
SAN DIEGO, March 21, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Dr. Randall Kaye as Chief Medical Officer (CMO). Dr. Philip Perera, who has led the clinical development and medical affairs activities since the launch of Longboard, has retired as CMO while remaining with Longboard in an advisory role. "On behalf of the board, shareholders, and our employees, I want to thank Phil for his tremendous contributions," said Kevin R. Lind, Longboard's President and Chief Executive Officer. "His outstanding leade
Initiated the Phase 1b/2a PACIFIC Study, evaluating LP352 in participants with developmental and epileptic encephalopathies (DEEs)LP352 demonstrated statistically significant reduction of epileptiform event frequency and duration in the scn1lab zebrafish model of Dravet syndromeLP659 IND submission remains on track for second half of 2022Cash position expected to support operations into 2024 based on current business plan SAN DIEGO, March 03, 2022 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported financ
SAN DIEGO, Nov. 17, 2021 (GLOBE NEWSWIRE) -- Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced the appointment of Jane Tiller, MBChB, FRCPsych, to its board of directors. "We are thrilled to further strengthen the deep expertise of our Board with the addition of Dr. Tiller. Jane brings knowledge across multiple therapeutic areas including neuroscience, and a deep understanding and successful track record in strategy and execution in global clinical development and medical affairs," stated Kevin R. Lind, Longboard's President and Chief Executive Officer.
Baird analyst Joel Beatty maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Outperform and raises the price target from $36 to $60.
As of July 3, 2024, three stocks in the health care sector could be flashing a real warning to investors who value momentum as a key criteria in their trading decisions. The RSI is a momentum indicator, which compares a stock’s strength on days when prices go up to its strength on days when prices go down. When compared to a stock’s price action, it can give traders a better sense of how a stock may perform in the short term. An asset is typically considered overbought when the RSI is above 70, according to Benzinga Pro. Here's the latest list of major overbought players in this sector. Harrow Inc (NASDAQ:HROW) On June 21, Craig-Hallum analyst Chase Knickerbocker maintained Har
Citigroup analyst David Hoang maintains Longboard Pharmaceuticals (NASDAQ:LBPH) with a Buy and raises the price target from $40 to $45.
DEEp OCEAN is the first pivotal clinical trial designed to study DEEs broadly Initial sites activated with additional sites expected to be activated in the coming weeks Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today announced that it has initiated its global Phase 3 DEEp OCEAN Study evaluating its investigational drug bexicaserin for the treatment of seizures associated with Developmental and Epileptic Encephalopathies (DEEs) in participants two years of age and older. "The initiation of our second global Phase 3 clinical trial, DEEp OCEAN in DEEs, is a
Positive opinion of Paediatric Investigation Plan for bexicaserin issued by European Medicines Agency (EMA) Paediatric Committee (PDCO) for children down to the age of 2 years Recently initiated Phase 3 global clinical trial (the DEEp SEA Study) to evaluate bexicaserin in Dravet syndrome for participants ages 2-65 years Longboard Pharmaceuticals, Inc. (NASDAQ:LBPH), a clinical-stage biopharmaceutical company focused on developing novel, transformative medicines for neurological diseases, today provided a corporate update and reported third quarter 2024 financial results. RECENT UPDATES: In October, announced an agreement for H. Lundbeck A/S (Lundbeck) to acquire Longboard in a stra
The proposed acquisition represents a significant step forward in Lundbeck's Focused Innovator strategy, adding a highly innovative and complementary product in late-stage development for Developmental and Epileptic Encephalopathies (DEEs) - an area of high unmet medical need The acquisition will enhance and complement Lundbeck's capabilities and presence within neuro-rare conditions The lead asset, bexicaserin, holds blockbuster potential and is in development for the treatment of DEEs in a program enrolling patients diagnosed with Dravet syndrome, Lennox-Gastaut syndrome, and other DEE syndromes Bexicaserin has shown encouraging anti-seizure effects to date in preclinical and clini
4 - Longboard Pharmaceuticals, Inc. (0001832168) (Issuer)